MODIFICATION
B -- B-Special studies and analysis-not R&D
- Notice Date
- 9/5/2002
- Notice Type
- Modification
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-201404-NQ
- Response Due
- 9/19/2002
- Point of Contact
- Cynthia Brown, Purchasing Agent, Phone (301) 496-8608, Fax (301) 402-4513,
- E-Mail Address
-
cb106x@nih.gov
- Description
- *******This notice is CANCELLED IN ITS ENTIRETY**************** ********DUPLICATED REFER TO NCI-20140-NQ****************** The National Cancer Institute (NCI), Cancer Prevention Studies Branch (CPSB), Center for Cancer Research (CCR) intends on entering into a sole source contract with New York University, School of Medicine, 550 First Avenue, OVB-Admin 606, New York, NY 10016. The CPSB requires the purchase of data on serum IgG antiboides to whole-cell H. Pylori and the CagA antigen in cases of upper GI cancers and control, as to determine the association of the presence of H. Pylori and subsequent development of upper GI cancers. CPSB/CCR conducts research in areas related to cancer prevention aimed at lowering human cancer risk. Gastric and esophageal cancers, are the second and the eighth most common cancers in the world. Linxian, China, has some of the highest rates of esophageal cancer in the world as well as cardia cancer, the age-standardized incidence rate for cancer is approximately 130/100,000 nearly 30 fold higher than the rate observed in the U.S. Previous studies conducted by CPSB examined the association of H. Pylori with subsequent risk of cancers of the cardia and the body of the stomach, these associations have remained controversial, due to small sample sizes in previous studies. These studies were done by Dr. Blaser's lab at New York University and is essential that the results of this study be comparable to the previous study to have sound scientific overall results. NCI plans on conducting a large and definitive study, examining the association of H. Pylori and the risk of upper GI cancers. This study will have a great impact on the treatment of patients infected with H. Pylori, a bacterium that infects about half of the world's population. This study is part of a larger research program between China and the U.S., whose overall goal is to try to determine optimal strategies for the prevention and early detection of upper GI cancers in both China and U.S. The New York Uniersity School of Medicine is the only source known to the Government that can provide the above requriements specified. However, if any interested party believes it can meet the above requirements, it may submit a statement of capabilities. The capability statement and any other furnished information must be in writing and must contain sufficient detail to allow the NCI to determine if the party can fully meet the Government needs. Capability statements must be received in the contracting office no later than September 19, 2002. This action is pursuant to 41 USC 253(1) and under the authority of FAR 6.302-1. The requrement will be procured as a non-commercial item in accordance with FAR Part 13 and FAR clause 52.217-8 Option to Extend Services. If you have any questions, please contact Cynthia Brown, Purchasing Agent (301) 402-4509. A determination by the Government not to compete this proposed requirement based on responses to this notice is solely within the discretion of the Government. Information received shall be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. The NAICS Code: 541990, and the business size standard is $6.0 million.
- Record
- SN00158344-W 20020907/020905213314 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |